➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:


Last Updated: June 17, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Foretinib

Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug Foretinib?

Foretinib is an investigational drug.

There have been 8 clinical trials for Foretinib. The most recent clinical trial was a Phase 2 trial, which was initiated on April 1st 2014.

The most common disease conditions in clinical trials are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, and Carcinoma. The leading clinical trial sponsors are GlaxoSmithKline, NCIC Clinical Trials Group, and [disabled in preview].

Recent Clinical Trials for Foretinib
A Study to Evaluate Foretinib in Subjects With Non-Small-Cell Lung CancerGlaxoSmithKlinePhase 2
Study of Foretinib in Combination With Lapatinib in Patients With Metastatic Breast CancerNCIC Clinical Trials GroupPhase 1/Phase 2
A Study of Foretinib in Patients With Recurrent/Metastatic Breast CancerNCIC Clinical Trials GroupPhase 2

See all Foretinib clinical trials

Clinical Trial Summary for Foretinib

Top disease conditions for Foretinib
Top clinical trial sponsors for Foretinib

See all Foretinib clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.